Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®

Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®

Abstract Multi-gene prognostic signatures including the Oncotype® DX Recurrence Score (RS), EndoPredict® (EP) and Prosigna® (Risk Of Recurrence, ROR) are widely used to predict the likelihood of distant recurrence in patients with oestrogen-receptor-positive (ER+), HER2-negative breast cancer. Here,...

Full description

Saved in:
Bibliographic Details
Main Authors: Richard Buus, Zsolt Szijgyarto, Eugene F. Schuster, Hui Xiao, Ben P. Haynes, Ivana Sestak, Jack Cuzick, Laia Paré, Elia Seguí, Nuria Chic, Aleix Prat, Mitch Dowsett, Maggie Chon U. Cheang
Format: article
Language:EN
Published: Nature Portfolio 2021
Subjects:
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Online Access:https://doaj.org/article/ab6604a1505e46ae8d5a30ae6561a42c
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/ab6604a1505e46ae8d5a30ae6561a42c

Similar Items